Treatment with granulocyte colony–stimulating factor for mobilization of bone marrow cells in patients with acute myocardial infarction

Kuethe, Friedhelm; Figulla, Hans R.; Herzau, Michael; Voth, M.; Fritzenwanger, Michael; Opfermann, Thomas; Pachmann, Katharina; Krack, Andreas; Sayer, Herbert G.; Gottschild, D; Werner, Gerald S.

doi:10.1016/j.ahj.2005.04.030

Cited by 94 publications

(50 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This conclusion is partly contradicted by the study by Kuethe et al, who used gated SPECT to assess the changes in wall perfusion and wall motion score and radionuclide ventriculography to evaluate the evolution of ejection fraction in patients treated by granulocyte-colony stimulating factor compared with a placebo group. They registered a significant improvement in both wall motion and perfusion scores in the treated patients, together with a significant increase in ejection fraction, whilst the patients under placebo therapy showed neither perfusion nor functional improvements [120]. Most recently, Beeres et al used gated SPECT to examine the effect of intramyocardial injection of autologous bone marrow-derived cells on perfusion and function in patients with severe, drug-refractory chronic ischaemia [121].…”

Section: Gated Spect For the Evaluation Of Left Ventricular Volumes Amentioning

confidence: 99%

The expanding role of left ventricular functional assessment using gated myocardial perfusion SPECT: the supporting actor is stealing the scene

Sciagrà

2007

Eur J Nucl Med Mol Imaging

View full text Add to dashboard Cite

Background Gating of single-photon emission computed tomography (SPECT) has significantly improved the reliability and diagnostic accuracy of myocardial perfusion imaging. The functional parameters derived from this technique, mainly left ventricular volumes and ejection fraction, have been demonstrated to be accurate and reproducible. They are able to increase the detection of severe and extensive coronary artery disease and show a significant incremental prognostic power over perfusion abnormalities. Therefore, the importance given to gated SPECT functional data has progressively grown. Discussion This circumstance has further expanded the indications for myocardial perfusion imaging and strengthened its position among the different imaging modalities. Moreover, several studies show that the evaluation of ventricular function may have a leading part in justifying the execution of perfusion scintigraphy in various clinical conditions. Aim Aim of this review is to describe this evolution of gated SPECT functional assessment from a supporting rank with respect to perfusion, to a main actor position in the field of cardiac imaging.

show abstract

Section: Gated Spect For the Evaluation Of Left Ventricular Volumes Amentioning

confidence: 99%

The expanding role of left ventricular functional assessment using gated myocardial perfusion SPECT: the supporting actor is stealing the scene

Sciagrà

2007

Eur J Nucl Med Mol Imaging

View full text Add to dashboard Cite

show abstract

“…Early clinical trials have demonstrated that G-CSF treatments show beneficial effects to improve cardiac function and myocardial perfusion in patients with acute myocardial infarction (AMI) [9][10][11][12][13] and chronic ischemic heart disease 14,15) . Although three subsequent double-blind placebo-controlled trials showed that G-CSF therapy failed to improve left ventricular restoration in AMI patients 16) , recent metaanalysis suggested that G-CSF may potentially benefit AMI patients with impaired left ventricular ejection fraction at baseline and when therapy is initiated early 17) .…”

Section: Introductionmentioning

confidence: 99%

Appropriate doses of Granulocyte-Colony Stimulating Factor Reduced Atherosclerotic Plaque Formation and Increased Plaque Stability in Cholesterol-Fed Rabbits

Matsumoto

Watanabe

Ueno

et al. 2010

JAT

View full text Add to dashboard Cite

Aim:To evaluate the dose-response effects of granulocyte-colony stimulating factor (G-CSF) on atherosclerosis, we examined how G-CSF treatment at different concentrations affects atherosclerotic plaque formation in the aorta of cholesterol-fed rabbits. Methods: Japanese White rabbits (n 8 each) fed on a 1.5% cholesterol diet were subcutaneously injected with G-CSF at 50 (GL), 100 (GM), or 300 g/kg/day (GH) for five days, or with 3 cycles of G-CSF at 100 g/kg/day at 3-week intervals (GM3), or human serum albumin (Control). The extent and composition of atherosclerosis was evaluated 14 weeks after cholesterol feeding. Results: Although G-CSF treatment did not affect plasma lipid levels, the percentage of aortic surface involvement in the GM3 group was significantly decreased (p 0.05) compared with the Control group. Histological analysis revealed that the intima media ratio was also diminished in GM and GM3 groups. The extent of intimal smooth muscle cell accumulation was higher in GL and GM3 groups than in the Control group. TIMP-2 mRNA expression in the aortic tissue was increased by G-CSF treatment. Conclusions: Our results suggest that appropriate doses of G-CSF reduced atherosclerotic plaque formation and increased plaque stability in cholesterol-fed rabbits.J Atheroscler Thromb, 2010; 17:84-96.

show abstract

“…Encouraged by pre-clinical data, the first clinical trials to evaluate the feasibility and safety of G-CSF appeared in 2004/2005. G-CSF was utilized to mobilize stem cells and/or treat patients after percutaneous coronary intervention (PCI) [22][23][24] and confirmed that this new type of treatment could be tested with a minimum of security, although some adverse effects were proposed [25].…”

Section: Clinical Trialsmentioning

confidence: 99%

“…1b). Initially, as requested, clinical investigations were performed with a limited number of patients, with or without a placebo group and in an openlabel or single-blind design [22][23][24][25][26][27]. All confirmed the safety and feasibility of G-CSF treatment.…”

Section: Clinical Trialsmentioning

confidence: 99%

Granulocyte Colony Stimulating Factor in the Treatment of Cardiac Ischemic Disease. A Decade has Passed: Is it Time to Give Up?

Louzada

Werneck-de-Castro

2011

Cardiovasc Drugs Ther

View full text Add to dashboard Cite

Treatment with granulocyte colony–stimulating factor for mobilization of bone marrow cells in patients with acute myocardial infarction

Cited by 94 publications

References 24 publications

The expanding role of left ventricular functional assessment using gated myocardial perfusion SPECT: the supporting actor is stealing the scene

The expanding role of left ventricular functional assessment using gated myocardial perfusion SPECT: the supporting actor is stealing the scene

Appropriate doses of Granulocyte-Colony Stimulating Factor Reduced Atherosclerotic Plaque Formation and Increased Plaque Stability in Cholesterol-Fed Rabbits

Granulocyte Colony Stimulating Factor in the Treatment of Cardiac Ischemic Disease. A Decade has Passed: Is it Time to Give Up?

Contact Info

Product

Resources

About